Prospective Study to Assess the Efficacy and Safety of Lanreotide 120 mg as a Palliative Treatment of Clinical Symptoms Associated With Malignant Intestinal Obstruction in Inoperable Patients.

Trial Profile

Prospective Study to Assess the Efficacy and Safety of Lanreotide 120 mg as a Palliative Treatment of Clinical Symptoms Associated With Malignant Intestinal Obstruction in Inoperable Patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Dec 2014

At a glance

  • Drugs Lanreotide (Primary)
  • Indications Peritoneal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Dec 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 01 Feb 2013 Planned End Date changed from 1 Jul 2012 to 1 Jul 2013 as reported by ClinicalTrials.gov.
    • 13 Jul 2012 Planned end date changed from 1 Mar 2012 to 1 Jul 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top